Workday Announces Fiscal 2025 Third Quarter Financial ResultsThe 15th playing of the RSM Classic has officially come and gone, and the field of local pros fell short of getting the honors of winning in front of the home course faithful. Entering the weekend with a successful 10 of 14 local golfers making the cut, the optimism was high that someone who calls Sea Islands' Seaside and Plantation courses home would have a chance to walk down the 18th green with an opportunity to win. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.
Ajman strengthens investment cooperation with IrelandInvestors may wonder whether the time to buy Amazon ( AMZN -0.64% ) has come and gone. While the company played key roles in pioneering the e-commerce and cloud computing industries, its market cap is now around $2.1 trillion. Given its massive size, investors could reasonably wonder whether relatively smaller growth stocks would make better investments now. Yet further research shows why investors should not write Amazon off as a mature, slow-growth stock just yet. Three factors indicate that it can still deliver market-beating returns despite its size. 1. Amazon's growth businesses First, investors should understand that they should not look to Amazon's online sales business for rapid expansion. With that part of the business logging single-digit percentage revenue growth for the past several quarters, it is likely not driving increases in Amazon stock. Amazon Web Services (AWS) is a different story. It continues to be the cloud infrastructure industry's leader. Additionally, its ability to apply artificial intelligence (AI) and run AI workloads gives it a critical role in today's tech industry. Moreover, its revenue for the first three quarters of 2024 grew by 18% to $79 billion, outpacing the company's 10% overall growth. Most importantly, 62% of Amazon's operating income came from AWS, demonstrating why it's arguably the most critical segment to the company's growth story. Nonetheless, it is likely not the only part. Within its North America and international segments, it operates digital advertising businesses, third-party seller services, and subscription services that are growing revenues at double-digit percentage levels. Although Amazon does not reveal the separate operating incomes of these businesses, they are likely helping to drive the company's growth. 2. The balance sheet Not surprisingly, the benefits of Amazon's growth businesses extend to its balance sheet. The company's liquidity is a staggering $88 billion, a level matched by few other companies. Admittedly, the $58 billion Amazon carries in long-term debt diminishes that liquidity somewhat. Still, it is largely low-interest debt with maturity dates decades into the future. Thus, one can assume that Amazon will probably earn returns from its cash and equivalents stockpile that exceed the interest rates it's paying, which should further bolster its balance sheet. Moreover, Amazon generated $48 billion in free cash flow over the last 12 months. Cash flows at those levels give it tremendous flexibility to invest in its enterprises or buy new businesses without diminishing its liquidity. Thus, Amazon can afford to maintain its leadership positions in the cloud and AI while it continues to innovate in the businesses tied to e-commerce. 3. Valuation While it continues to innovate, one sign that the company may have begun to mature is its valuation. Amazon stock historically traded at elevated P/E ratios as it either took losses or accepted reduced profitability to invest more capital back into its businesses. So investors used to Amazon trading at P/E ratios of between 50 and 120 may be surprised to find that its earnings multiple has fallen to about 43. Moreover, that has happened during a period when the company is reaping the benefits of its investments. In the first nine months of 2024, the company's net income was $39 billion, almost twice as much as its profit of $20 billion during the same period last year. Analysts believe its net income growth will slow to 20% in 2025. Still, given Amazon's history of high valuations, investors may want to capitalize on today's lower earnings multiple by adding shares. Investing in Amazon stock Ultimately, instead of viewing Amazon's massive market cap as a reason to treat it as a value stock, investors should continue to buy Amazon for growth. Despite its overall size, Amazon includes AWS and many comparatively smaller growth businesses that can keep its revenue growth in the double-digit percentages. Moreover, its staggering liquidity and free cash flow should help keep these businesses and any future enterprises it pursues vibrant. Finally, Amazon's valuation has fallen relative to its P/E ratios of the past. With its revenue and earnings growth expected to remain robust, growth investors can likely still beat the market by buying and holding Amazon stock.
For airports, background music no longer is an afterthought
Want the best VPN with a 74% discount? The NordVPN Black Friday deal is live and runs until December 10. This is the perfect chance to lock in a 2-year plan for the low cost of $2.99 per month, with an extra 3 months for free. NordVPN is one of the top-rated VPNs for good reason. The VPN is known for its fast speeds, wide choice of server locations in 100+ countries, and ability to bypass regional blocks and censorship. Whether you want to stream Netflix on vacation, use public WiFi without fear of hackers, or prevent ISPs from monitoring your activities , NordVPN is exceptional. Best of all? NordVPN is offering its 2-year plan with a whopping 74% discount + 3 months extra for free. The NordVPN Black Friday and Cyber Monday deal runs from October 16 until December 10. Follow the link on this page to enable the automatic Black Friday coupon. This will get you 27 months of NordVPN Basic for just $80.73. You would have to spend much more at its regular price of $12.99 per month. Now you can see why this deal is so tempting! You can also save 74% on the NordVPN Plus and Ultimate plans. More on that below. The NordVPN Plus plan gives you unlimited use of the VPN with Threat Protection Pro and NordVPN’s secure password manager . It costs just $3.89 per month, which is an extremely fair price for unlimited use of a VPN with advanced DNS-based filtering and a reliable password manager. The NordVPN Ultimate plan provides access to the entire Nord Technologies advanced security suite. It will cost you $159 for 27 months (down from $626.13). This plan is discounted to just $5.89 monthly, a 74% reduction! It comes with access to the VPN , the password manager , the advanced version of NordVPN’s anti-malware, anti-tracker, and ad-blocking service , one Terabyte of encrypted cloud storage, and $5k in scam loss insurance. That is incredible value because with Google, 2TB of cloud storage costs $10 per month ($5 for 1 TB of storage). NordVPN gives you the VPN, password manager, Advanced Threat Protection, and $5k of cyber insurance for just 89 cents more per month . NordVPN’s Black Friday offer launched on October 16 and will run until December 16. That means the promotion covers both Black Friday and Cyber Monday! Why should I get NordVPN this Black Friday? NordVPN is a premium VPN provider based in Panama. Panama is a superb country for a privacy service to be based in, thanks to its lack of mandatory data retention directives or invasive surveillance agencies. This puts it beyond invasive jurisdictions like the US, the UK, and the EU. The VPN has apps for Windows , Mac , iOS, Android , Linux , and Firestick . This ensures that you and your family can use the VPN on smartphones, tablets, and computers you happen to own. Each NordVPN subscription allows you to connect ten devices consecutively. This is usually more than enough for larger families and power users, allowing you to use the VPN at home, at work, in school, and when connected to public WiFi hotspots . When it comes to providing value for money, NordVPN is hard to beat. The VPN comes with a choice of protocols, including OpenVPN and its custom WireGuard fork, NordLynx. The latter is designed from the ground up to offer robust security and faster streaming speeds. We tested the VPN thoroughly and found it could access all the international streaming services we tried it with. This includes watching Netflix US , Hulu, HBO Max, Disney+, Peacock, BBC iPlayer , Amazon Prime, and others. Below, we have included all the features you get with NordVPN (even if you opt for the Basic plan, which offers the VPN as a standalone): NordVPN is dedicated to user privacy, security, and transparency. This is why it goes the extra mile to earn your trust. It has completed three independent audits, which verified its strict no-logs policy and the security of its apps. NordVPN subscribers also get access to Meshnet . This powerful feature provides VPN-protected remote access for seamless file sharing. NordVPN subscriptions also come with a free Smart DNS service that can give you a US IP address on smart TVs, game consoles, and any other device that won’t let you install a VPN directly. This is perfect for accessing US platforms like Netflix US on these devices. Learn more in our full review of NordVPN , where we explain why it’s considered one of the top-rated VPNs! Should I wait for a better deal? Based on previous NordVPN deals from the last two years, Black Friday is the best time to get a new VPN subscription. We don’t expect NordVPN to offer a better deal at Christmas. So, if you need a VPN, we advise jumping in now! Otherwise, you may regret it! All NordVPN subscriptions come with a 30-day money-back guarantee . This allows you to pick the discounted plan that best suits your needs - and test it risk-free for a month. If you decide you don’t need it— for any reason —simply ask for a full refund. No pressure! Looking for more discounts and tech deals? Check out our Black Friday roundup .Flock Safety Announces Full Compliance with FBI's Newly-Released Criminal Justice Information Services (CJIS) Policy Update
Tesla’s Game-Changer: Driving Into the Gaming World! Revolutionizing How We Play in Our Cars.CARLSBAD, Calif. , Dec. 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZATM (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (sHTG) that can lead to potentially life-threatening acute pancreatitis (AP). TRYNGOLZA is the first-ever FDA-approved treatment that significantly and substantially reduces triglyceride levels in adults with FCS and provides clinically meaningful reduction in AP events when used with an appropriate diet (≤20 grams of fat per day). TRYNGOLZA is self-administered via an auto-injector once monthly. Experience the full interactive Multichannel News Release here: https://www.multivu.com/ionis-pharmaceuticals/9295551-en-tryngolza-olezarsen-fda-approval "Today's FDA approval of TRYNGOLZA heralds the arrival of the first-ever FCS treatment in the U.S. – a transformational moment for patients and their families. For the first time, adults with FCS can now access a treatment that substantially reduces triglycerides and the risk of debilitating and potentially life-threatening acute pancreatitis," said Brett P. Monia , Ph.D., chief executive officer, Ionis. "We are proud of our long-standing partnership with the FCS community and are grateful to the patients, families and investigators who participated in our clinical studies, enabling Ionis to make this new treatment a reality. The FDA approval of TRYNGOLZA is also a pivotal moment for Ionis, representing our evolution into a fully integrated commercial-stage biotechnology company – a goal we set out to achieve five years ago. With our rich pipeline of potentially life-changing medicines, we expect TRYNGOLZA to be the first in a steady cadence of innovative medicines we will deliver independently to people living with serious diseases." The FDA approval was based on positive data from the global, multicenter, randomized, placebo-controlled, double-blind Phase 3 Balance clinical trial in adult patients with genetically identified FCS and fasting triglyceride levels ≥880 mg/dL. In the Balance study, TRYNGOLZA 80 mg demonstrated a statistically significant placebo-adjusted mean reduction in triglyceride levels of 42.5% from baseline to six months (p=0.0084). Reductions from baseline to 12 months were further improved, with TRYNGOLZA achieving a placebo-adjusted 57% mean reduction in triglycerides. TRYNGOLZA also demonstrated a substantial, clinically meaningful reduction in AP events over 12 months; one patient (5%) experienced one episode of AP in the TRYNGOLZA group compared with seven patients (30%) who experienced 11 total episodes of AP in the placebo group. TRYNGOLZA demonstrated a favorable safety profile. The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and at a >3% higher frequency than placebo) were injection site reactions (19% and 9%, respectively), decreased platelet count (12% and 4%, respectively) and arthralgia (9% and 0%, respectively). Results from the Phase 3 Balance study were previously published in The New England Journal of Medicine (NEJM). "With no treatment options previously available, we were limited to relying only on extremely strict diet and lifestyle changes as the sole preventative treatment option," said Alan Brown , M.D., FNLA, FACC, FAHA, clinical professor of medicine, Rosalind Franklin University of Medicine and Science ; Balance trial investigator. "The FDA approval of TRYNGOLZA is an important moment for people living with FCS, their families and physicians who now, for the first time, have a treatment that significantly lowers triglycerides and decreases the risk of potentially life-threatening acute pancreatitis events, as an adjunct to a low-fat diet. I am excited to have a medicine I can prescribe to my patients that has been shown to change the course of their disease." FCS is a rare, genetic, potentially life-threatening form of sHTG that prevents the body from breaking down fats and severely impairs the body's ability to remove triglycerides from the bloodstream due to an impaired function of the enzyme lipoprotein lipase (LPL). While healthy levels for adults are below 150 mg/dL, people with FCS often have triglyceride levels of more than 880 mg/dL and often have a history of pancreatitis. Those living with FCS have a high risk of potentially fatal AP, which is a painful inflammation of the pancreas, and chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS can also experience psychological and financial stress, which can significantly impact their quality of life. In the U.S., FCS is estimated to impact up to approximately 3,000 people, the vast majority of whom remain undiagnosed. "As a rare and difficult to diagnose disease, FCS has a profound impact on the lives of patients and families. Many people living with FCS have experienced severe pain their whole lives – sometimes so intense they require lengthy hospitalization stays – and struggle through life with daily fatigue, nausea, brain fog and stomach pain," said Lindsey Sutton Bryan , co-founder and co-president, FCS Foundation. "Until now, our treatment options have been limited, relying on diet alone to try to manage triglyceride levels and keep acute pancreatitis attacks at bay. For the first time, adults with FCS have seen their hope for a treatment become a reality." TRYNGOLZA will be available in the U.S. before year end. Ionis is committed to helping people access the medicines they are prescribed and will offer a suite of services designed to meet the unique needs of the FCS community through Ionis Every StepTM. As part of Ionis Every Step , patients and healthcare providers will have access to services throughout the treatment journey provided by dedicated Patient Education Managers and Ionis Every Step Case Managers, including insurance and affordability support, as well as services and resources, such as disease and nutrition education. Visit TRYNGOLZA.com for more information. TRYNGOLZA was reviewed by the FDA under Priority Review and had previously been granted Fast Track designation for the treatment of FCS, Orphan Drug designation and Breakthrough Therapy designation. Olezarsen is undergoing review in the European Union and regulatory filings in other countries are planned. Olezarsen is currently being evaluated in three Phase 3 clinical trials – CORE, CORE2 and ESSENCE – for the treatment of sHTG. Olezarsen has not been reviewed or approved for the treatment of sHTG by regulatory authorities. Webcast Ionis will hold a webcast today at 6:45pm ET to discuss the FDA approval. Interested parties may access the webcast here . A webcast replay will be available for a limited time. About TRYNGOLZATM (olezarsen) TRYNGOLZATM (olezarsen) was approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). TRYNGOLZA is an RNA-targeted medicine designed to lower the body's production of apoC-III, a protein produced in the liver that is a key regulator of triglyceride metabolism. It is the only treatment currently indicated in the U.S. for FCS, a potentially life-threatening disease. For more information about TRYNGOLZA, visit TRYNGOLZA.com . IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS TRYNGOLZA is contraindicated in patients with a history of serious hypersensitivity to TRYNGOLZA or any of the excipients in TRYNGOLZA. Hypersensitivity reactions requiring medical treatment have occurred. WARNINGS AND PRECAUTIONS Hypersensitivity Reactions Hypersensitivity reactions (including symptoms of bronchospasm, diffuse erythema, facial swelling, urticaria, chills and myalgias) have been reported in patients treated with TRYNGOLZA. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to promptly seek medical attention and discontinue use of TRYNGOLZA if hypersensitivity reactions occur. ADVERSE REACTIONS The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and >3% higher frequency than placebo) were injection site reactions, decreased platelet count and arthralgia. Please see full Prescribing Information for TRYNGOLZA. About Familial Chylomicronemia Syndrome (FCS) FCS is a rare, genetic disease characterized by extremely elevated triglyceride levels. It is caused by impaired function of the enzyme lipoprotein lipase (LPL). Because of limited LPL production or function, people with FCS cannot effectively break down chylomicrons, lipoprotein particles that are 90% triglycerides. FCS is estimated to impact up to approximately 3,000 people in the U.S. People living with FCS are at high risk of acute pancreatitis (AP) in addition to other chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS are sometimes unable to work, adding to the burden of disease. About the Balance Study Balance is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of olezarsen in patients with FCS at six and 12 months. The primary endpoint was the percent change from baseline in fasting triglyceride levels at six months compared to placebo. Secondary endpoints included percent changes in triglyceride levels at 12 months, percent changes in other lipid parameters and adjudicated acute pancreatitis event rates over the treatment period. Following treatment and the end-of-trial assessments, patients were eligible to enter an open-label extension study to continue receiving olezarsen once every four weeks. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis has discovered and developed six marketed medicines for serious diseases, including breakthrough medicines for neurologic and cardiovascular diseases. Ionis has a leading pipeline in neurology, cardiology and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) , LinkedIn and Instagram . Ionis Forward-Looking Statements This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of TRYNGOLZA, Ionis' technologies and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including but not limited to those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31, 2023 , and most recent Form 10-Q, which are on file with the SEC. Copies of these and other documents are available at www.Ionis.com . Ionis Pharmaceuticals® and TRYNGOLZATM are trademarks of Ionis Pharmaceuticals, Inc. Ionis Investor Contact: D. Wade Walke , Ph.D. info@ionis.com 760-603-2331 Ionis Media Contact: Hayley Soffer media@ionis.com 760-603-4679 View original content: https://www.prnewswire.com/news-releases/tryngolza-olezarsen-approved-in-us-as-first-ever-treatment-for-adults-living-with-familial-chylomicronemia-syndrome-as-an-adjunct-to-diet-302336747.html SOURCE Ionis Pharmaceuticals, Inc.
Esusu Creates Over $46.9 Billion in New Credit Tradelines for Renters Across the Country
Jeff Bezos denies Tesla stock story and shares a laugh with Elon Musk
Pacers vs. Pelicans Injury Report Today – November 25
BERKELEY, Calif. (AP) — Andrej Stojakovic converted 11 of 15 from the free throw line and scored 20 points as California held off a late rally to post an 83-77 win over Sacramento State in the Cal Classic tournament on Sunday. Cal came into its tournament without three starters, Jovan Blacksher Jr., DJ Campbell and BJ Omot and the Golden Bears earned back-to-back wins over Air Force and the Hornets. Stojakovic scored a career-high 21 points and freshman guard Jeremiah Wilkinson stepped up with career-best 23 points against the Falcons. Against Sacramento State, Wilkinson came off the bench to score 16 points. Sacramento State took an early 12-7 lead after Emil Skytta hit a pair of free throws five minutes into the game, but Wilkinson hit back-to-back buckets and Stojakovic drew a foul on a three-point attempt and hit all three foul shots to take a 14-12 lead and the Bears pulled away to take a 40-33 lead at intermission. Julian Vaughns knocked down a trey three minutes into the second half to pull Sacramento State even at 43 and his free throw put the Hornets in front. Ryan Petraitis and Wilkinson hit back-to-back 3-pointers to put Cal up 51-47 and the Bears never trailed the rest of the way. Petraitis finished with 13 points, five assists and three steals for Cal (5-1). Joshua Ola-Joseph and Mady Sissoko each added 10 points. Jacob Holt scored 25 points with eight rebounds, two assists and a steal to lead Sacramento State (1-4). Vaughns scored 18 points and EJ Neal added 16. The game was just the third meeting between schools separated by roughly 80 miles, and first since 1992. Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college basketball: https://apnews.com/hub/ap-top-25-college-basketball-poll and https://apnews.com/hub/college-basketball
Hayleys Energynet partners Hengyang Ritar Power for greener energy futureNone
